A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Exclusion Criteria

• •Cardiogenic shock
• •Current hospitalisation for acute heart failure primarily triggered by pulmonary embolism, cerebrovascular accident, or acute myocardial infarction (AMI)
• •Current hospitalisation for acute heart failure not caused primarily by intravascular volume overload;
• •Below interventions in the past 30 days prior to randomisation or planned during the study:
• •* Major cardiac surgery, or TAVI (Transcatheter Aortic Valve Implantation), or PCI, or Mitraclip
• •* All other surgeries that are considered major according to investigator judgement
• •* Implantation of cardiac resynchronisation therapy (CRT) device
• •* cardiac mechanical support implantation
• •* Carotid artery disease revascularisation (stent or surgery)
• •Acute coronary syndrome / myocardial infarction, stroke or transient ischemic attack (TIA) in the past 90 days prior to randomisation
• •Heart transplant recipient, or listed for heart transplant with expectation to receive a transplant during the course of this trial (according to investigator judgement), or planned for palliative care for HF, or currently using left ventricular assist device (LVAD) or intra-aortic balloon pump (IABP) or any other type of mechanical circulatory support, or patients on mechanical ventilation, or patients with planned inotropic support in an outpatient setting
• •Haemodynamically significant (severe) uncorrected primary cardiac valvular disease planned for surgery or intervention during the course of the study (note: secondary mitral regurgitation or tricuspid regurgitation due to dilated cardiomyopathy is not excluded unless planned for surgery or intervention during the course of the study)
• •Impaired renal function, defined as eGFR \< 20 mL/min/1.73 m2 as measured during hospitalization (latest local lab measurement before randomisation) or requiring dialysis
• •Type 1 Diabetes Mellitus (T1DM)
• •History of ketoacidosis, including diabetic ketoacidosis (DKA)